Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
Aim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. High cost of such treatment and risk of adverse events related to it requires definition of strict indicati...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
Gastro LLC
2013-10-01
|
| Edice: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Témata: | |
| On-line přístup: | https://www.gastro-j.ru/jour/article/view/1233 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|